contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Equity Research Analyst

Philip Coombes

BioPorto är verksamt inom bioteknik. Bolaget tillverkar och marknadsför tester för diagnostisering av diverse allvarliga sjukdomar. Produktportföljen består av egenutvecklade antikroppsläkemedel som används för farmaceutisk bruk samt inom diverse forskningssammanhang. Produkterna återfinns på global nivå och används exempelvis vid behandling och analys av fetma, diabetes och diverse allergier.

BioPorto

Bioporto released preliminary figures for fiscal year 2024 yesterday after market closed.
Guidance 2024
Revenue FY 24 DKK 40 mio.
Adj ebitda loss DKK 75&#x2013;90 mio. midpoint -82,5&#xa0;
&#xa0;
Preliminary figures 2024
Revenue DKK 36,2 mio. vs. DKK 31 mio (FY23) +17% YoY and vs. Guidance -9,5%
Adj ebitda loss DKK 68-73 mio. vs. Guidance 75-90 mio.
&#xa0;Revenue for the fourth quarter DKK 7,9 mio. vs. DKK 6,6 mio (Q4-23) +20%
&#xa0;CEO in Bioporto comments &#x201c;Overall I am very satisfied with the preliminary results for 2024. Having a very ambitious revenue target, we managed to deliver solid revenue growth based on increased Research Use Only Sales of NGAL in the US. We look forward to the US commercial launch of the FDA cleared ProNephro AKI (NGAL) this year. For adjusted EBITDA, the improved estimate is primarily due to tight cost control and lower than expected costs related to our clinical study in the US for adult usage of ProNephro AKI (NGAL).&#x201d;&#xa0;
&#xa0;The company will release the annual report on March 20 &#x2013; 2025 and will participate in HC Andersen Capital seminar January 16 &#x2013; 2025.
Sign up for seminar here: <a href="https://hcaccapital-stag.agillic.eu/api/api/webcopy/view/pdxGGzYzkDEKaH0dnmoR5xOQDPZRhZYzLj6-m7vgzAv_H_zo9VLnJojkg9kk0YPf:IFpD7QxTI2AhPEenxN0e0w==/Seminar+-+16+januar+2025+-+FOR+SELSKABER.html?lgn_uid=LmEzQ0U6MTc2NDA3NTYyNsXp3jzvV4-zlgA3e8t-iIw!&amp;lgn_uid=LmEzQ0U6MTc2NDA3ODE5MlxsP6c1elsMk87F6ZrZyh0!&amp;ea=zFipDItxE1kqewoy-zH4pRFe3GmZkCSLgZqnSP3Ebafz7sduo_8i9iO4jVJToysrdU1aPhDgnBqiO9xb36CL5w==:MdGsvnHBrBoGz1RKVFvq_Q==" target="_blank" rel="noopener">HCA Capital seminar</a>
Disclaimer: HC Andersen Capital receives payment from Bioporto for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 08:15 AM 06.01-2025.